Source: Investing.com ↗

Novartis DM1 drug fails late-stage trial, clouding development outlook

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.02%

BTC/USDT

$85,790.00

-0.09%

ETH/USDT

$2,732.05

-0.29%

ZEC/USDT

$1,609.92

+7.12%

XRP/USDT

$1.59

+3.83%